HOME >> MEDICINE >> NEWS
VELCADE (Bortezomib) receives European marketing authorisation

ghted that marketing authorisation for VELCADE has been granted, as it is the first major advance for patients with multiple myeloma in more than a decade, and marks the company's commitment to Oncology." said Ken Watters, European Medical Director, Ortho Biotech.

"The approval of VELCADE today brings renewed hope to thousands of European multiple myeloma patients and their families" said Eric Low, Executive Director, International Myeloma Foundation (UK). "The multiple myeloma advocacy community has campaigned tirelessly over the years for cutting edge treatments such as VELCADE to be made available to patients, this is a very proud day", he continued.

The findings of a pre-specified interim analysis from an ongoing phase III trial which compared VELCADE to dexamethasone in refractory multiple myeloma patients found a statistically significant improvement in time to disease progression the primary endpoint of the trial in patients receiving VELCADE compared to patients receiving high-dose dexamethasone. Patients in the control arm of the trial were given the opportunity to switch to VELCADE as soon as possible based on an interim analysis that found a statistically significant improvement in TTP in patients receiving VELCADE compared to patients receiving dexamethasone.

VELCADE has a generally predictable, manageable safety profile (with appropriate monitoring and if necessary, dose modification). VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. There are approximately 50 ongoing clinical trials (in Europe and the US) investigating the potential of VELCADE in all stages of multiple myeloma and other cancers.

A single licence has been granted to market VELCADE in the 15 member states of the EU, plus Norway and Iceland. In addition it will be available in the 10 accession countries.

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Ph
'"/>

Contact: Eva Reynolds
eva_reynolds@uk.bm.com
44-20-7831-6262
Burson-Marsteller
28-Apr-2004


Page: 1 2 3

Related medicine news :

1. VELCADE(TM) data confirms long-term survival
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... ... February 17, 2017 , ... The ... systems change designed to further positively impact the health and wellness of our ... long considered it our duty to seriously consider releasing our assets beyond our ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ET, http://www.fdanews.com/deviceapproval ... asking before selecting an FDA approval pathway? , How should they evaluate ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... announced today that Karen Pilley has been promoted to Chief Executive Officer. ... shifting healthcare paradigm – a shift that demands the transition from pay-for-service to ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer ... Molecular Medicine Tri-Conference February 20 – 22 in San Francisco. As part of ... anatomic and molecular pathology workflow solution, as well as its new precision medicine ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... and Markets has announced the addition of the "Pharmaceutical Contract Manufacturing ... ... the US, Canada , Japan , ... of World. Annual estimates and forecasts are provided for the period 2015 ... Market data and analytics are derived from primary and secondary research. ...
(Date:2/17/2017)... Feb. 17, 2017   FormFast , the leader ... new partnership with Engage , one of the ... . FormFast will serve as the forms automation ... with MEDITECH .  FormFast is ... to complement and enhance the electronic health record. FormFast,s ...
(Date:2/17/2017)... -- Noble Capital Markets announced today that it has initiated ... EPIX ). The report was issued by Noble,s Head ... ESSA Pharmaceuticals is a clinical stage biopharmaceutical company ... lead compound EPI-506, is a small molecule oral drug ... receptor, thereby has potential to overcome some of the ...
Breaking Medicine Technology:
Cached News: